Stephen D. Allen

NTP Nano Tech Projects SRL develops Nano-Eye, an advanced optical-laser microscopy device that can achieve optical resolutions below the micron size. The company was founded by Adolfo Carloni, Gianluca Maroncelli and Massimo Galavotti in 2012 and is headquartered in Sant'Angelo in Vado, Italy.

Solexa Ltd. was a developer of instruments for analyzing genes in the process of drug development. It's research methods have included DNA sequencing, gene expression, genotyping and micro-RNA analysis to allow scientists to analyze individual genomes for drug development and personalized medicine. The company was headquartered in Saffron Walden, UK.

Direct Conversion AB manufactures and supplies X-Ray detectors such as cadmium telluride (CdTe) detectors. Its products include XC-THOR, XC-HYDRA, XC-TDI, XC-ACTAEON, SNAP 225, SNAP 150 and SNAP 100X2. The firm’s products are used in the dental, medical, welding, industrial, food and security industries. The company was founded in 1997 and is headquartered in Danderyd, Sweden.

Solexa, Inc. used to create DNA cloning and analyses technologies to enhance gene discovery. It also used to provide genomics, genetics and proteomics technologies to assist the customers in the field of pharmaceutical and agriculture. The company was located in Hayward, CA.

Part of Genting Bhd., DNAe Group Holdings Ltd. is a healthcare company based in London, UK. DNAe is commercializing its pioneering semiconductor sequencing technology for healthcare applications, including infectious disease and cancer testing and monitoring. The British company is developing Lidia-seq™, a user-friendly, direct-from-specimen platform that performs genomic analysis on a microchip, to provide actionable information to clinicians. DNAe's initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. The company's major shareholder is Genting Berhad, a Malaysian-based investor with a growing portfolio of investments in cutting-edge life sciences companies. The company was founded in 2003 by Christofer Toumazou. The CEO is Samuel Reed.